Dr. Daniel Duprez Seeks Alternative Treatments for Statin-Intolerant Patients
Dr. Daniel Duprez, M.D., Ph.D., Professor of Medicine, Donald and Patricia Garofalo Chair in Preventive Cardiology, and Professor of Epidemiology and Community Health, was recently asked to participate in a ground-breaking clinical trial to study the efficacy and safety of a new fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with primary hypercholesterolemia who are intolerant to statins. Hypercholesterolemia, particularly an increase in low-density lipoprotein (LDL) cholesterol (LDL-C) levels, constitutes a major risk for the development of atherosclerosis and coronary heart disease (CHD), the leading cause of death and disability in the Western world. This study is being funded by Regeneron Pharmaceuticals, Inc, and is actively recruiting patients in 24 locations worldwide.
This multi-national, multi-center clinical study looks to enroll 250 patients with primary hypercholesterolemia and moderate, high, or very high cardiovascular (CV) risk, who are intolerant to statins. These patients are then provided the new drug for 39 weeks to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow it to be used safely.
It is hoped that after the trial period, the patients using this new treatment will demonstrate a reduction of low-density lipoprotein (LDL) cholesterol (LDL-C) levels in comparison with today’s commonly used treatments.